Treasury yields jump, gold suffers, tech stocks lag after Pfizer COVID-19 trial news

/ / News

A Phase 3 trial showing the COVID-19 vaccine being developed by Pfizer and BioNTech was more than 90% effective hit several asset classes, as well as boosting stock futures . The yield on the 10-year Treasury jumped 9 basis points to 0.91%, and gold futures sunk $33 an ounce. The Nasdaq 100 contract , propped up by the tech heavyweights, underperformed the broader market with a 0.7% advance.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.